The students of the Higher Vocational Education Program for Pharmaceutical Technician at Frans Schartaus Handelsinstitut are conducting their second LIA (Learning in the Workplace) period from 31 October to 20 December. They then graduate the same week and are ready to start working.
In February 2021, Oncopeptides' drug candidate for relapsed or refractory multiple myeloma, Pepaxto®, was approved by the FDA for use in the USA. This marked an astonishing accomplishment for a small Swedish biotech company, but also the start of significant regulatory hurdles.
Curious to find out about clinical evidence for medical device software under the new EU regulations? Look no further than our brand new white paper.
This is the fourth white paper in a series published by Clarvin AB, Morris Law, Kickfile, and Devicia AB - Your Medical Device CRO. And for the second time, also in collaboration with SwedenBIO, the national association for the life science industry in Sweden.